From Glutamatergic Dysfunction to Cognitive Impairment: Boundaries in the Therapeutic of the Schizophrenia

E-ISSN： 1873-4316|13|8|1543-1548

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.13, Iss.8, 2012-06, pp. : 1543-1548

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3813-3828

Bentham Science Publishers

Access to resources Recommend Favorite

The Concept of Salience Network Dysfunction in Schizophrenia: From Neuroimaging Observations to Therapeutic Opportunities

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 21, 2012-11 ,pp. : 2324-2338

Bentham Science Publishers

Access to resources Recommend Favorite

Recent advances in treating cognitive impairment in schizophrenia

By Galletly Cherrie

Psychopharmacology, Vol. 202, Iss. 1-3, 2009-01 ,pp. : 259-273

Springer Publishing Company

Access to resources Recommend Favorite

Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future

Current Pharmaceutical Design, Vol. 20, Iss. 32, 2014-10 ,pp. : 5127-5138

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia

By Harvey Philip D.

Drugs, Vol. 66, Iss. 11, 2006-01 ,pp. : 1465-1473

Adis International

Access to resources Recommend Favorite